Skip to main content

Advertisement

Figure 1 | Journal of Hematology & Oncology

Figure 1

From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Figure 1

(A) Maximum reduction in target lesions and (B) complete remission in 80-year-old female with multiple subcutaneous and skin lesions of multifocal primary cutaneous DLBCL leg type. Waterfall plot of maximum reduction in target lesions for all patients with data before and after treatment with dacetuzumab. Each bar represents change in the sum of the product of perpendicular diameters (SPD) for an individual patient (*denotes pictured case study).

Back to article page